# Junta clínica — PT-pseudo_25007bb807d7 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_25007bb807d7",
  "pid": "PT-pseudo_25007bb807d7",
  "task": 1,
  "psa": 17.0,
  "age": 61,
  "months": 1,
  "pirads": "5",
  "psad": 0.462,
  "psav": 1.29,
  "psap": 16.1,
  "vol": 36.82,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.85766834,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 17 ng/mL. PI-RADS 5. PSAD 0.46. Prostate volume 37 mL. csPCa 0.86.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "83 kg",
    "height": "193 cm",
    "bmi": "22.3",
    "bp": "122/68 mmHg",
    "hr": "74 bpm",
    "smoking": "Ex-smoker (16 pack-yr, quit 2015)",
    "last_dental": "3 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "19 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent prostate-specific antigen elevation prompted mpMRI scheduling."
    },
    {
      "s": "History",
      "t": "A 61-year-old office administrator entered the clinical pathway after a sustained prostate-specific antigen rise spanning three years. Lower urinary tract symptoms are minimal, scoring four on the IPSS questionnaire, while haematuria, pelvic discomfort, and unexplained weight loss are absent. Smoking history totals 16 pack-years, with cessation occurring in 2015; weekend hiking and roughly 11 units of alcohol weekly characterize his routine. He resides with his wife, who acts as his primary contact. Recent ophthalmological intervention involved uneventful cataract surgery, necessitating large-print materials for correspondence. Cardiovascular status remains stable, confirmed by a cardiology review in autumn 2024 that required no active interventions. There is a complete absence of prior urological procedures, comorbid conditions, or current medications."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. General inspection shows a well-nourished individual with stable vital signs, alongside an absence of palpable lymphadenopathy or hepatosplenomegaly."
    }
  ],
  "occupation": "office administrator",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "11 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_25007bb807d7
Task: 1

Encounter: Urology - outpatient on 19 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 17.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.462 ng/mL²
  - PSA velocity: 1.29 ng/mL/yr
  - Prior PSA: 16.1 ng/mL
  - Prostate volume: 36.82 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.85766834 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 17 ng/mL. PI-RADS 5. PSAD 0.46. Prostate volume 37 mL. csPCa 0.86.

Vitals: weight 83 kg, height 193 cm, BMI 22.3, BP 122/68 mmHg, HR 74 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2015).

Chief complaint: Persistent prostate-specific antigen elevation prompted mpMRI scheduling.

History: A 61-year-old office administrator entered the clinical pathway after a sustained prostate-specific antigen rise spanning three years. Lower urinary tract symptoms are minimal, scoring four on the IPSS questionnaire, while haematuria, pelvic discomfort, and unexplained weight loss are absent. Smoking history totals 16 pack-years, with cessation occurring in 2015; weekend hiking and roughly 11 units of alcohol weekly characterize his routine. He resides with his wife, who acts as his primary contact. Recent ophthalmological intervention involved uneventful cataract surgery, necessitating large-print materials for correspondence. Cardiovascular status remains stable, confirmed by a cardiology review in autumn 2024 that required no active interventions. There is a complete absence of prior urological procedures, comorbid conditions, or current medications.

Physical examination: DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. General inspection shows a well-nourished individual with stable vital signs, alongside an absence of palpable lymphadenopathy or hepatosplenomegaly.

Patient info: office administrator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 11 units / week; exercise Hiking on weekends; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024).
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.90
  uncertainty  +/- 0.04 epistemic (95% band 0.83-0.97); among patients I cannot tell apart the outcome was 0.46 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = none recorded (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 61 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 17 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 36.82 mL (1% of my signal; from log_vol, vol) · PSA density = 0.462 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.86 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 5
  important  prior biopsy = None
  noted      age = 61 · DRE = Normal · PSA = 17 ng/mL · prostate volume = 36.82 mL · PSA density = 0.462 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: clear — the rule matched the reading urologist in 24 of 24 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 23 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.08: PI-RADS 5, PSA 9.0, PSAD 0.409, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P5 in a man with high PSA"
  2. distance 1.14: PI-RADS 5, PSA 22.0, PSAD 0.696, age 68, DRE Normal -> BIOPSY (clear). He wrote: "Biopsy-naive PIRADS 5 needs biopsy"
  3. distance 1.26: PI-RADS 5, PSA 7.0, PSAD 0.329, age 63, DRE Normal -> BIOPSY (clear). He wrote: "P5 in a man with rapid increasing PSA"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   PI-RADS = 5
  important  PSA = 17 ng/mL
  noted      prior biopsy = None · age = 61 · DRE = Normal · prostate volume = 36.82 mL · PSA density = 0.462 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: clear — the precedents agree (1.00) and the library is right 92% of the time in this situation out of fold

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 23 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   PI-RADS = 5
  important  age = 61 · PSA = 17 ng/mL
  noted      prior biopsy = None · family history = not opened (0 of 91) · DRE = Normal · prostate volume = 36.82 mL · PSA density = 0.462 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using the PI-RADS score to trigger biopsy, stating, "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naive patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]." This requires a decision based on the PI-RADS score, which for this patient is 5.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your bid of BIOPSY p(biopsy) = 0.90 is high, but the guideline treats the PI-RADS score as the primary trigger. The guideline suggests that a PI-RADS $\ge 3$ triggers biopsy, and this patient's PI-RADS score of 5 falls into this category. The guideline does not explicitly address the variable 'prior biopsy' as a decisive factor in this context, but it notes that biopsy-naive patients are a population where the risk of missing cancer is higher. The guideline requires the PI-RADS score, which is 5, to be the primary factor for the decision. The guideline requires the patient to be biopsy-naive, which this patient is.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy: None - the guideline suggests that biopsy is triggered by the PI-RADS score, and the patient being biopsy-naive is a factor that increases the risk of missing cancer.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trajectory: the guideline does not explicitly state a threshold for PSA trend, but the patient's PSA velocity of 1.29 ng/mL/yr is a factor in risk stratification.
laboratory_results - the full panel: the guideline references PSA density thresholds in relation to risk stratification, which is relevant given the patient's PSAD of 0.462.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case strongly points towards biopsy based on the PI-RADS score and the patient being biopsy-naive, which aligns with the EAU guideline.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI prose indicate whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the significance of the PSA velocity of 1.29 ng/mL/yr in the context of the guideline?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy status, surveillance protocol, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What should be established regarding the prior biopsy status to confirm the risk stratification?
  Q2. What should be established regarding the lesion comparison in the radiology report to assess potential change?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose indicates that the lesion is compared against an earlier study by stating "Evaluation of elevated PSA (17.0 ng/mL) and clinical suspicion of malignancy."
psa_trend
The significance of the PSA velocity of 1.29 ng/mL/yr in the context of the guideline is that the guideline does not explicitly state a threshold for PSA trend, but the patient's PSA velocity of 1.29 ng/mL/yr is a factor in risk stratification.
previous_notes
The management context regarding the prior biopsy status is that there was "None" prior biopsy, and the surveillance protocol is not explicitly detailed beyond arranging imaging to clarify the aetiology.

WHAT I DID NOT OPEN
laboratory_results, family-history anamnesis, and pathology report were left closed because they were not explicitly required by the Moderator's list for this decision point.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the right peripheral zone, as per the radiology_report.
Patient is biopsy-naive, which increases the risk of missing cancer, as noted in the EAU guideline discussion.
AGAINST sampling this patient now
Nothing

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 17.00 ng/mL over 5 points spanning 31 months; velocity +2.18 ng/mL per year; doubling time about 63 months.
PROJECTION at 6 months: 52.6 ng/mL, conformal 95% band 15.1-183.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 17 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.81
  uncertainty  +/- 0.07 epistemic (95% band 0.68-0.94), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 17 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 36.82 mL (4% of my signal; from log_vol, vol) · PSA density = 0.462 (0% of my signal; from psad_calc) · comorbidity = none recorded (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.90  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.81  ('firm' tier, fusion_nolab; weight 4.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           None                         E1:DEC E3:DEC cohort:IMP library:not E2:—            -> noted
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:— E2:—                    -> not_used (raised from noted by the board)
  age          61                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          17 ng/mL                     E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          36.82 mL                     E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.462                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.86                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:DEC library:DEC E2:—            -> decisive
  comorbidity  none recorded                E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) appear to address the moderator's questions regarding the prior biopsy status and lesion comparison, as the registrar reported that the radiology report indicates the lesion is compared against an earlier study, and the previous notes state there was "None" prior biopsy.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of BIOPSY, as the cohort criterion (PI-RADS $\ge 3$) fired, and the registrar confirmed the PI-RADS 5 lesion and the biopsy-naive status.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What should be established regarding the prior biopsy status to confirm the risk stratification? Answered by the registrar: "there was 'None' prior biopsy".
Q2. What should be established regarding the lesion comparison in the radiology report to assess potential change? Answered by the registrar: "The mpMRI prose indicates that the lesion is compared against an earlier study by stating 'Evaluation of elevated PSA (17.0 ng/mL) and clinical suspicion of malignancy.'"

WHAT CARRIES WEIGHT, AND WHY
<pirads>: decisive: 5 (carried by EXPERT-COHORT and EXPERT-FUSION) because the guideline explicitly uses this score as the primary trigger, and the cohort criterion matched the reading urologist in 24 of 24 cases.
<prior biopsy>: decisive: None (carried by EXPERT-STRUCTURED and EXPERT-FUSION) because the panel protocol explicitly noted this as decisive, and the registrar confirmed "None" prior biopsy.
<psa>: important: 17 ng/mL (carried by EXPERT-STRUCTURED and EXPERT-FUSION) as it is noted by both experts, supporting the overall concern level.
My confidence in the record as it stands is clear, as all documents listed by the trace model were opened and directly addressed the moderator's questions.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with biopsy firmly, as the PI-RADS 5 score in a biopsy-naive patient aligns with the EAU guideline and the consensus of the panel protocol.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

61 y/o, PSA 17 ng/mL, PI-RADS 5, biopsy-naive. PI-RADS 5 mandates biopsy, supported by elevated PSA density of 0.462. No prior pathology to reconcile this finding.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
